Julius A. Vida
Geen lopende functies
Profiel
Julius A.
Vida is the founder of Vida International Pharmaceutical Consultants, which was founded in 1993.
He held the title of President from 1993 to 2018.
Dr. Vida's former jobs include Director positions at Medarex, Inc. from 1994 to 2009, Orphan Medical, Inc., Spectrum Pharmaceuticals, Inc. as Lead Director, YM BioSciences, Inc., FibroGen, Inc., Almac Sciences (Scotland) Ltd., Almac Group Ltd., and OsteoScreen, Inc. He also held the title of VP-Business Development & Strategic Planning at Bristol Myers Squibb Co. from 1975 to 1993.
Dr. Vida's education history includes a graduate and doctorate degree from Carnegie Mellon University, an MBA from The Trustees of Columbia University in The City of New York, and an undergraduate degree from Eotvos Lorand University.
Eerdere bekende functies van Julius A. Vida
| Bedrijven | Functie | Einde |
|---|---|---|
| Vida International Pharmaceutical Consultants | Founder | 10-06-2018 |
| OsteoScreen, Inc. | Director/Board Member | 10-06-2018 |
Almac Sciences (Scotland) Ltd.
 Almac Sciences (Scotland) Ltd. Chemicals: SpecialtyProcess Industries Part of Chemical Synthesis Services Business, Almac Sciences (Scotland) Ltd. is a British company that produces custom peptides and proteins. The private company is based in Penicuik, UK. | Director/Board Member | 10-06-2018 |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Director/Board Member | 27-08-2009 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Director/Board Member | 28-11-2007 |
Opleiding van Julius A. Vida
| Carnegie Mellon University | Doctorate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Eotvos Lorand University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Orphan Medical, Inc.
 Orphan Medical, Inc. Pharmaceuticals: MajorHealth Technology Orphan Medical, Inc. develops and markets pharmaceutical and health care products. The company was founded in 1993 and is located in Minnetonka, MN. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Almac Sciences (Scotland) Ltd.
Almac Sciences (Scotland) Ltd. Chemicals: SpecialtyProcess Industries Part of Chemical Synthesis Services Business, Almac Sciences (Scotland) Ltd. is a British company that produces custom peptides and proteins. The private company is based in Penicuik, UK. | Process Industries |
Almac Group Ltd.
 Almac Group Ltd. Pharmaceuticals: MajorHealth Technology Almac Group Ltd. manufactures and distributes pharmaceutical products. The firm’s services include diagnostics, API services and chemical development, pharmaceutical development, analytical and solid state services, clinical services, clinical technologies and commercial services. The company was founded by Allen McClay in 2002 and is headquartered in Craigavon, the United Kingdom. | Health Technology |
| Vida International Pharmaceutical Consultants | |
| OsteoScreen, Inc. |
